drugset / Trial / NCT00855101

A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

NCT00855101

Phase 1 Completed 35 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study is to assess the plasma concentration-time profile of voriconazole in adults receiving 7-day intravenous treatment and 6.5-day oral treatment. This study is also to assess the safety profile of voriconazole during the treatment period.

Timeline

Start
2009-04
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 4 mg/kg Intravenous
Subject Voriconazole Small molecule 200 mg Intravenous

Indications

No indication recorded.